Celltrion is lined up to copy 8 of the blockbuster drugs on this tracker, which earned $74.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Celltrion's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Steqeyma |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Stoboclo |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Osenvelt |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Keytruda CT-P51 |
Merck | Biosimilar | 2028 | Phase 3; filed in Korea | $31.7B |
| Darzalex CT-P44 |
Johnson & Johnson | Biosimilar | 2029 | Phase 3 | $14.3B |
| Cosentyx CT-P55 |
Novartis | Biosimilar | 2029 | Filed in Canada (Jun 2026) and the EU (Jul 2026) | $6.7B |
| Taltz CT-P52 |
Eli Lilly | Biosimilar | 2030 | Early development | $3.6B |
| Tremfya CT-P68 |
Johnson & Johnson | Biosimilar | 2031 | Phase 1 approved in Korea (Jul 2026) | $5.2B |
Company facts: Stock Analysis. Each drug page lists sources for these entries. Brand sales show the size of the market, not Celltrion's share of it.